Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 307

1.

SELDI-TOF proteomic analysis and cancer detection.

Henderson NA, Steele RJ.

Surgeon. 2005 Dec;3(6):383-90, 422. Review.

PMID:
16353858
2.

Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery.

Seibert V, Ebert MP, Buschmann T.

Brief Funct Genomic Proteomic. 2005 May;4(1):16-26. Review.

3.

[Proteomic profiling: the potential of Seldi-Tof for the identification of new cancer biomarkers].

Solassol J, Marin P, Maudelonde T, Mangé A.

Bull Cancer. 2005 Sep;92(9):763-8. Review. French.

PMID:
16203265
4.

Identification of protein biomarkers in Dupuytren's contracture using surface enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS).

O'Gorman D, Howard JC, Varallo VM, Cadieux P, Bowley E, McLean K, Pak BJ, Gan BS.

Clin Invest Med. 2006 Jun;29(3):136-45.

PMID:
17058431
5.

SELDI-TOF-MS of saliva: methodology and pre-treatment effects.

Schipper R, Loof A, de Groot J, Harthoorn L, Dransfield E, van Heerde W.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Feb 15;847(1):45-53. Epub 2006 Oct 27.

PMID:
17070117
6.

SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma.

Geng X, Wang F, Li YG, Zhu GP, Zhang WM.

J Exp Clin Cancer Res. 2007 Dec;26(4):505-8.

PMID:
18365545
8.

Protein profiling for cancer biomarker discovery using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and infrared imaging: a review.

Bakry R, Rainer M, Huck CW, Bonn GK.

Anal Chim Acta. 2011 Mar 25;690(1):26-34. doi: 10.1016/j.aca.2011.01.044. Epub 2011 Mar 2. Review.

PMID:
21414433
9.

Direct-tissue SELDI-TOF mass spectrometry analysis: a new application for clinical proteomics.

Bouamrani A, Ternier J, Ratel D, Benabid AL, Issartel JP, Brambilla E, Berger F.

Clin Chem. 2006 Nov;52(11):2103-6. Epub 2006 Sep 21.

10.
11.

Contributions of advanced proteomics technologies to cancer diagnosis.

Ciordia S, de Los Ríos V, Albar JP.

Clin Transl Oncol. 2006 Aug;8(8):566-80. Review.

PMID:
16952845
12.

Proteomic patterns: their potential for disease diagnosis.

Xiao Z, Prieto D, Conrads TP, Veenstra TD, Issaq HJ.

Mol Cell Endocrinol. 2005 Jan 31;230(1-2):95-106. Review.

PMID:
15664456
13.
14.

SELDI-TOF serum proteomics and colorectal cancer: a current overview.

Gemoll T, Roblick UJ, Auer G, Jörnvall H, Habermann JK.

Arch Physiol Biochem. 2010 Oct-Dec;116(4-5):188-96. doi: 10.3109/13813455.2010.495130. Epub 2010 Jul 8. Review.

PMID:
20615064
15.

Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry.

Engwegen JY, Gast MC, Schellens JH, Beijnen JH.

Trends Pharmacol Sci. 2006 May;27(5):251-9. Epub 2006 Apr 4. Review.

PMID:
16600386
16.
17.

Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.

Han KQ, Huang G, Gao CF, Wang XL, Ma B, Sun LQ, Wei ZJ.

Am J Clin Oncol. 2008 Apr;31(2):133-9. doi: 10.1097/COC.0b013e318145b98b.

PMID:
18391596
18.

Identification of serum biomarkers for nasopharyngeal carcinoma by proteomic analysis.

Wei YS, Zheng YH, Liang WB, Zhang JZ, Yang ZH, Lv ML, Jia J, Zhang L.

Cancer. 2008 Feb 1;112(3):544-51.

19.

Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.

Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, Wells M, Guerrero M, Asara JM, Libermann TA, Afdhal NH.

Clin Cancer Res. 2008 Jan 15;14(2):470-7. doi: 10.1158/1078-0432.CCR-07-0586.

20.

Clinical proteomics in breast cancer: a review.

Gast MC, Schellens JH, Beijnen JH.

Breast Cancer Res Treat. 2009 Jul;116(1):17-29. doi: 10.1007/s10549-008-0263-3. Epub 2008 Dec 11. Review.

PMID:
19082706
Items per page

Supplemental Content

Write to the Help Desk